Tech Transfer eNews Blog
Industry-Sponsored Research Management sample issue

U of Pittsburgh start-up gets more than $5M in Series A round to develop antidote for carbon monoxide poisoning

By Jesse Schwartz
Published: May 16th, 2018

A University of Pittsburgh spinout has closed a Series A funding round of over $5 million to develop its antidote for carbon monoxide poisoning.

Globin Solutions will use the funds to advance preclinical development of its lead compound to optimize manufacturing and ensure that the antidote is safe in animals.

According to the Centers for Disease Control and Prevention, between 40,000 and 50,000 people are sent to the ER each year for carbon monoxide poisoning, while more than 400 are killed.

When carbon monoxide (CO) enters the body, it latches onto hemoglobin molecules that normally carry oxygen in the blood. Globin Solutions created a mutant version of the protein neuroglobin, a hemoglobin-like protein found in the brain, which binds strongly with CO to flush it out of the body.

The start-up’s solution is meant to be a better alternative to the current treatment option of transferring patients to one of the 250 facilities specifically equipped to provide hyperbaric oxygen therapy through pressurized chambers.

“It creates logistical barriers to treating people, transporting them in a timely fashion, particularly if they are based in a rural community,” says Jason Rose, assistant professor of medicine and bioengineering at the University of Pittsburgh and co-founder of Globin Solutions. “There’s a great need for an antidote that you could give locally to reduce some of these devastating effects.”

The Series A funding round was led by Tus Science & Technology Service Group, an enterprise firm in China, where the problem of CO poisoning appears to be growing. UPMC Enterprises, the tech transfer arm of the University of Pittsburgh Medical Center, also participated in the round.

Source: MedCity News

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment